These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 7795272)

  • 1. Deoxyspergualin: phase I clinical, immunologic and pharmacokinetic study.
    Havlin KA; Kuhn JG; Koeller J; Boldt DH; Craig JB; Brown TD; Weiss GR; Cagnola J; Phillips J; Harman G
    Anticancer Drugs; 1995 Apr; 6(2):229-36. PubMed ID: 7795272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of deoxyspergualin in patients with advanced cancer.
    Muindi JF; Lee SJ; Baltzer L; Jakubowski A; Scher HI; Sprancmanis LA; Riley CM; Vander Velde D; Young CW
    Cancer Res; 1991 Jun; 51(12):3096-101. PubMed ID: 2039989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of deoxyspergualin in metastatic breast cancer.
    Dhingra K; Valero V; Gutierrez L; Theriault R; Booser D; Holmes F; Buzdar A; Fraschini G; Hortobagyi G
    Invest New Drugs; 1994; 12(3):235-41. PubMed ID: 7896543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin.
    Dhingra K; Fritsche H; Murray JL; LoBuglio AF; Khazaeli MB; Kelley S; Tepper MA; Grasela D; Buzdar A; Valero V
    Cancer Res; 1995 Jul; 55(14):3060-7. PubMed ID: 7606728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of NKT-01.
    Tamura K; Niitani H; Oguro M; Ohno R; Sanpi K; Majima H; Masaoka T; Kimura I; Inagaki J; Suzuoki Y
    Cancer Chemother Pharmacol; 1995; 36(3):189-94. PubMed ID: 7781137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical antitumor activity and pharmacological properties of deoxyspergualin.
    Plowman J; Harrison SD; Trader MW; Griswold DP; Chadwick M; McComish MF; Silveira DM; Zaharko D
    Cancer Res; 1987 Feb; 47(3):685-9. PubMed ID: 3802074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of rhizoxin.
    Bissett D; Graham MA; Setanoians A; Chadwick GA; Wilson P; Koier I; Henrar R; Schwartsmann G; Cassidy J; Kaye SB
    Cancer Res; 1992 May; 52(10):2894-8. PubMed ID: 1581905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
    Ten Tije AJ; Verweij J; Sparreboom A; Van Der Gaast A; Fowst C; Fiorentini F; Tursi J; Antonellini A; Mantel M; Hartman CM; Stoter G; Planting AS; De Jonge MJ
    Clin Cancer Res; 2003 Aug; 9(8):2957-64. PubMed ID: 12912942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial and clinical pharmacology of elsamitrucin.
    Raber MN; Newman RA; Newman BM; Gaver RC; Schacter LP
    Cancer Res; 1992 Mar; 52(6):1406-10. PubMed ID: 1540949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I study of CHS 828 in patients with solid tumor malignancy.
    Hovstadius P; Larsson R; Jonsson E; Skov T; Kissmeyer AM; Krasilnikoff K; Bergh J; Karlsson MO; Lönnebo A; Ahlgren J
    Clin Cancer Res; 2002 Sep; 8(9):2843-50. PubMed ID: 12231525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule.
    Von Hoff DD; Kuhn JG; Havlin KA; Langevin AM; Brown TD; Weiss GR; Turner JN; Purvis J; Lucas VS; Bair KW
    Cancer Res; 1990 Dec; 50(23):7496-500. PubMed ID: 2253197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
    Thomas JP; Tutsch KD; Cleary JF; Bailey HH; Arzoomanian R; Alberti D; Simon K; Feierabend C; Binger K; Marnocha R; Dresen A; Wilding G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):465-72. PubMed ID: 12451473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
    Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
    Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
    Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
    Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762).
    Vasey PA; Bissett D; Strolin-Benedetti M; Poggesi I; Breda M; Adams L; Wilson P; Pacciarini MA; Kaye SB; Cassidy J
    Cancer Res; 1995 May; 55(10):2090-6. PubMed ID: 7743508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate.
    McDonald AC; Vasey PA; Adams L; Walling J; Woodworth JR; Abrahams T; McCarthy S; Bailey NP; Siddiqui N; Lind MJ; Calvert AH; Twelves CJ; Cassidy J; Kaye SB
    Clin Cancer Res; 1998 Mar; 4(3):605-10. PubMed ID: 9533527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacological study of merbarone.
    Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
    Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
    Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
    Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
    Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.